NASDAQ · Biotechnology

Kronos Bio, Inc. (KRON) Stock

$0.88 +1.49% NASDAQ: KRON Healthcare

Kronos Bio, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to the identification and advancement of innovative therapies for cancer.

Valuation

MetricValue
Price$0.88
Market Cap$53.65M
P/E Ratio-0.62
P/B Ratio0.60
P/S Ratio5.45
EPS (TTM)$-1.43
52-Week High$1.46
52-Week Low$0.65
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-69.80%
ROA-69.22%
ROCE-85.15%
Gross Margin100.00%
Operating Margin-943.21%
Net Margin-874.08%
Debt/Equity0.28
Current Ratio7.54

Annual Financials (USD)

Metric20202021202220232024
Revenue$0$0$0$6.0M$10.0M
Operating Profit$-58.0M$-151.0M$-137.0M$-122.0M$-93.0M
Net Profit$-64.0M$-149.0M$-129.0M$-113.0M$-86.0M
EPS$-1.19$-2.72$-2.30$-1.95$-1.43
Op Margin———-1937.5%-943.2%

Balance Sheet (USD)

Metric20202021202220232024
Total Assets$512.0M$391.0M$295.0M$213.0M$124.0M
Total Liabilities$46.0M$46.0M$50.0M$54.0M$37.0M
Cash$462.0M$340.0M$76.0M$64.0M$85.0M
Borrowings$32.0M$34.0M$31.0M$28.0M$25.0M

Cash Flow (USD)

Metric20202021202220232024
Operating Cash Flow$-38.0M$-118.0M$-91.0M$-79.0M$-65.0M
Investing Cash Flow$-170.0M$59.0M$-33.0M$66.0M$85.0M
Financing Cash Flow$264.0M$6.0M$1.0M$1.0M$0
Net Cash Flow$217.0M$-50.0M$-122.0M$-12.0M$20.0M
Free Cash Flow$-47.0M$-122.0M$-92.0M$-79.0M$-65.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.01
EV / EBITDA0.10
FCF Yield-121.97%
Quick Ratio7.54
Interest Coverage0.00
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ACHLAchilles Therapeutics plc $1.48 +0.68% -0.85 $60.83M 0.00%
ALVRAlloVir, Inc. $9.81 +4.14% -1.89 $49.48M 0.00%
ARPOAerpio Pharmaceuticals, Inc. $2.20 -0.90% -1.31 $53.67M 0.00%
BLUEbluebird bio, Inc. $4.97 — -0.20 $48.67M 0.00%
RENBLunai Bioworks Inc. $1.42 +0.00% 0.67 $32.92M 0.00%

About Kronos Bio, Inc.

Kronos Bio, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to the identification and advancement of innovative therapies for cancer. Its therapeutic strategy centers on modulating dysregulated transcription factors and the intricate transcriptional regulatory networks that fuel oncogenic activity. The company's primary investigational drug, entospletinib (ENTO), is an orally administered, selective inhibitor of spleen tyrosine kinase (SYK), designed for patients with acute myeloid leukemia. A registrational Phase 3 clinical trial is slated to evaluate ENTO in combination with induction chemotherapy for acute myeloid leukemia patients who possess NPM1 mutations. Furthermore, Kronos Bio is progressing KB-0742, an orally bioavailable cyclin dependent kinase 9 (CDK9) inhibitor, which is currently undergoing Phase 1/2 clinical assessment for the treatment of MYC-amplified solid tumors. Established in 2017, the company maintains its headquarters in San Mateo, California.

Kronos Bio, Inc. is headquartered in US.

Kronos Bio, Inc. (KRON) stock trades at $0.88 with a market capitalization of $53.65M. The stock is valued at a price-to-earnings (P/E) ratio of -0.62, price-to-book of 0.60, price-to-sales of 5.45. Over the past 52 weeks the stock has ranged between $0.65 and $1.46, and currently trades 39.7% below its 52-week high.

On profitability, Kronos Bio, Inc. generates a return on equity (ROE) of -69.80%, return on capital employed of -85.15%, an operating margin of -943.21%, a net profit margin of -874.08%.

Official website: kronosbio.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides